Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
复制标题
DOI：
10.1002/hed.20274
复制
发表时间：
2005-12-01
影响因子：
2.9
通讯作者：
Hong, RL
中科院分区：
文献类型：
--
作者：
Lin, CH;Yen, RF;Hong, RL
背景转移性腺样囊性癌（ACC）通常是一种惰性肿瘤，缺乏有效的治疗方法。我们研究了甲磺酸伊马替尼（一种强效的KIT酪氨酸激酶抑制剂）在KIT阳性转移性ACC患者中的疗效。在一项初步研究中，5例肺转移患者接受伊马替尼400 mg口服，每日两次治疗。分析这些患者肿瘤中c-kit和血小板衍生生长因子受体（PDGFR）-α的突变。在2至3周的短期治疗期间，5例患者中有3例出现疾病进展。3例患者在6个月内死于疾病。未发现c-kit和PDGFR-α基因突变。在伊马替尼治疗期间，我们观察到转移性ACC在短时间内意外的高进展率。使用伊马替尼治疗没有c-kit或PDGFR-α突变的癌症应谨慎对待。(c)2005 Wiley Periodicals，Inc.
Background. There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor. We studied the efficacy of imatinib mesylate, a potent inhibitor of KIT tyrosine kinase, in patients with KIT-positive metastatic ACC.Methods. Five patients with lung metastasis were treated in a pilot study with imatinib 400 mg by mouth twice a day. Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed.Results. Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks. Three patients died of disease within 6 months. No detectable mutations were found in c-kit and PDGFR-alpha.Conclusion. We observed an unexpected high progression rate of metastatic ACC within short periods during imatinib treatment. Use of imatinib to treat cancers without c-kit or PDGFR-alpha mutation should be approached with caution. (c) 2005 Wiley Periodicals, Inc.